Get the Stockscreener App
596.54
0.37%
2.22
After Hours:
596.54
Regeneron Pharmaceuticals Inc stock is traded at $596.54, with a volume of 666.04K.
It is up +0.37% in the last 24 hours and up +5.93% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$594.32
Open:
$588.48
24h Volume:
666.04K
Relative Volume:
0.63
Market Cap:
$63.32B
Revenue:
$14.09B
Net Income/Loss:
$4.50B
P/E Ratio:
15.19
EPS:
39.28
Net Cash Flow:
$2.96B
1W Performance:
+3.63%
1M Performance:
+5.93%
6M Performance:
-19.88%
1Y Performance:
-39.27%
1-Day Range:
$586.68
$598.56
1-Week Range:
$558.45
$598.56
52-Week Range:
$520.50
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
596.54 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ONC
Beigene Ltd Adr
|
233.37 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
72.58 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Bankrupt 23andMe sold for $256M—Who owns 15M DNA profiles now? - NewsBytes
Genetic data will be safeguarded with 23andMe sale, drugmaker vows - The Washington Post
Pharma giant Regeneron to buy genetics firm 23andMe for $256m - Tech in Asia
Regeneron acquires bankrupt 23andMe for 356 billion won amid data breach fallout - Chosunbiz
Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services - HIT Consultant
Regeneron Sees 23andMe Buy As Complement To Genetics PlatformClone - insights.citeline.com
23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron's Gene-Based Drug R&D Efforts - MedCity News
What's not included in the 23andMe deal, and who else was bidding - The Business Journals
23andMe Finds $256M Buyer in Regeneron After Chapter 11 Filing - Athletech News
Regeneron Acquires 23andMe for $256 Million, Expanding Its Genetic Data and Innovation Footprint - WebProNews
23andMe To Be Acquired By Tarrytown-Based Regeneron For $256M - Patch
Nuveen Asset Management LLC Sells 211,009 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Mufg Securities Americas Inc. Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Now we know who's getting 23andMe's DNA data. Meet Regeneron Pharmaceuticals. - Mashable SEA
23andMe to Be Bought by Biotech Company for $256 Million - The New York Times
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million - USA Today
Biotechnology company Regeneron buying 23andMe for $256 million - The Journal Gazette
Regeneron plans to buy 23andme from bankruptcy for $256M - BioWorld MedTech
Regeneron Pharmaceuticals to buy 23andMe for over $250 million - wng.org
23andMe to be acquired by NY-based Regeneron in $256 million deal - KTVU
23andMe assets being sold to Regeneron Pharma for $256M - MSN
Wachtell-Led Regeneron To Buy 23andMe, Gaining User Data - Law360
23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction - Investor's Business Daily
Bankrupt 23andMe Just Sold Off All Your DNA Data - futurism.com
Why Regeneron is buying 23andMe - Endpoints News
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal - Benzinga
Focus Partners Wealth Purchases 6,213 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Struggling DNA testing firm 23andMe to be bought for $256m - BBC
Regeneron Pharmaceuticals to buy 23andMe for $256M - ABC News
Regeneron in $256M deal to acquire human genetics and bio company - Westfair Communications
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data - Reuters
Bankrupt DNA testing company 23andMe to be bought by Regeneron - CBC
Regeneron to acquire 23andMe DNA testing firm. How that could impact your genetic data - Lohud
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data | Business Information & News | FE - Westlaw Today
From $6 Billion to Bankruptcy: The Fall and Sale of 23andMe to Regeneron - FXLeaders
Regeneron agrees to buy bankrupt 23andMe - Yahoo Finance
Bankrupt 23andMe Expected to Be Purchased for $256M - People.com
Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million - WSJ
Regeneron Win Underscores Importance of Simple Market Definition - Bloomberg Law News
Regeneron to buy bankrupt DNA testing company 23andMe for $256 million - Mezha.Media
23andMe (and Your Genetic Data) Sold to Regeneron in Bankruptcy Auction - Gizmodo
Doubling down on genetics-guided drug development, Regeneron to buy 23andMe - FirstWord Pharma
Regeneron to Acquire 23andMe with Winning $256M Bid - Genetic Engineering and Biotechnology News
OraSure stock rises following Regeneron’s 23andMe acquisition - Investing.com
Regeneron Buys 23andMe in Bankruptcy Auction - Investopedia
Regeneron to buy bankrupt DNA testing company 23andMe for $256M - NewsNation
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions - New York Post
OraSure rises as seen benefitting from 23andMe/Regeneron deal - Seeking Alpha
Regeneron to buy 23andMe out of bankruptcy for $256 mn - Medical Xpress
Regeneron Pharmaceuticals Picks Up 23andMe Assets In Bankruptcy Auction - Finimize
Regeneron buys bankrupt 23andMe for $256m - Yahoo Finance
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.78%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):